ANTI-CD38-ANTIKÖRPER

European patent · EP2658871 · In force

Register entry

Publication number
EP2658871
Application number
EP11811633
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Dec 30, 2011
Published
Nov 6, 2013
Granted
May 2, 2018
Protection ends at the latest
Dec 29, 2031
Next annual fee due
Dec 31, 2026
IPC classes
C07K 16/28 (2006.01)
A61P 35/02 (2006.01)
Priority
US 201161470406 P 31.03.2011
US 201061428699 P 30.12.2010
US 201161485104 P 11.05.2011
US 201161470382 P 31.03.2011
PCT application
PCT/US2011/068235 30.12.2011
PCT publication
WO2012/092612 05.07.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 1, 2026

    Change

    Published in Swissreg on 01.01.2026

  2. Jan 1, 2025

    Change

    Published in Swissreg on 01.01.2025

  3. Jan 1, 2024

    Change

    Published in Swissreg on 01.01.2024

  4. Jan 1, 2023

    Change

    Published in Swissreg on 01.01.2023

  5. May 2, 2018

    Granted

    Published in Swissreg on 02.05.2018

Parties

Holder

Takeda Pharmaceutical Company Limited

1-1 Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka 541-0045, JP

Inventor

ELIAS, Kathleen Ann

San Diego, CA 92121, US

LANDES, Gregory

San Diego, CA 92121, US

SINGH, Shweta

San Diego, CA 92121, US

KORVER, Wouter

San Diego, CA 92121, US

DRAKE, Andrew Walling

San Diego, CA 92121, US

HAAK-FRENDSCHO, Mary

San Diego, CA 92121, US

SNELL, Gyorgy Pal

San Diego, CA 92121, US

BHASKAR, Vinay

San Diego, CA 92121, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.